INTRODUCTION {#S5}
============

Necrotizing enterocolitis (NEC) continues to be a leading cause of morbidity and mortality in premature infants ([@R1]). Although the etiology of NEC is unclear, current evidence associates NEC with diverse pre- and postnatal factors such as placental insufficiency, chorioamnionitis, gut ischemia, altered bacterial colonization, viruses, and blood transfusions. These conditions presumably disrupt the mucosal barrier and promote translocation of luminal bacteria, which trigger an inflammatory reaction in the developing intestine ([@R2]).

Several cross-sectional studies show that NEC is associated with increased expression of inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, and IL-8/CXC-motif ligand 8 (CXCL8) in both plasma and affected tissues ([@R3]--[@R7]). These cytokines are potential therapeutic targets in NEC because (a) preclinical evidence indicates that these cytokines can disrupt the epithelial barrier and augment intestinal injury ([@R8]); and (b) monoclonal antibodies and/or small molecule inhibitors are now available that can block the effect of these inflammatory mediators. At the same time, concerns remain about possible harm from anti-cytokine therapy in preterm infants because many so-called 'inflammatory' cytokines play important developmental roles in the gut mucosa and mucosa-associated immune system ([@R5],[@R9]). Evidence from cross-sectional studies has its limitations because cytokine expression changes during normal gestational maturation and with co-morbidities associated with prematurity ([@R10]). To elucidate the pathophysiological role of cytokines in NEC, there is a need for longitudinal comparison of cytokine concentrations before and after onset of NEC and in infants who eventually developed NEC vs. others who did not. Towards this goal, we performed a secondary analysis of data obtained as part of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Neonatal Research Network Cytokine Study, a prospective multi-center study in which extremely-low-birth-weight (ELBW) infants were enrolled and clinical information and serial cytokine measurements were collected from birth through postnatal day 21 ([@R11]).

We have shown recently that premature infants may be at risk of NEC due to a developmental deficiency of TGF-β in the intestine, which is further accentuated during NEC ([@R12]). In the present study, we hypothesized that decreased tissue expression of TGF-β is a systemic phenomenon reflected in blood samples from patients who develop NEC. In addition, in view of the epidemiological association of NEC with fetal inflammation related to chorioamnionitis, prolonged rupture of membranes, and *Ureaplasma* infections ([@R13],[@R14]), we hypothesized that infants who develop NEC have elevated serum cytokine levels in early neonatal period and prior to the onset of NEC.

PATIENTS AND METHODS {#S6}
====================

We conducted a secondary analysis of clinical and biological data collected as part of the NICHD Cytokine Study ([@R11]). Preterm neonates with birth weight 401--1000 g were enrolled after obtaining written informed consent from the parent(s). Whole blood spots were collected on standardized filter paper and frozen on postnatal days 0--1 (D1), 3±1 (D3), 7±1 (D7), 14±3 (D14), and 21±3 (D21) using an established protocol that has been shown to maintain sample quality and consistency for cytokine measurements over extended periods of time (\>20 years) ([@R15]). Clinical data were collected by trained research coordinators and analyzed at a central data coordinating center. Concentrations of 25 cytokines/inflammatory mediators were measured in blood spot eluates using a multiplex flow cytometric immunoassay based on laser detection of color-encoded antibody-tagged microspheres (xMAP assay, Luminex Corp., Austin, TX) ([@R15]). The following analytes were included in the immunoassay panel: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-12, IL-17, IL-18, TNF, lymphotoxin-alpha (LT-α)/TNF-beta, interferon (IFN)-γ, granulocyte macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP)-1/CC ligand (CCL)-2, macrophage inflammatory protein (MIP)-1α/CCL3, MIP-1β/CCL4, regulated on activation, normal T-cell expressed and secreted (RANTES)/CCL5, IL-8/CXCL8, IL-10, TGF-β~1~, matrix metalloproteinase (MMP)-9, soluble IL-6 receptor (sIL6R), triggering receptor expressed on myeloid cells (TREM)-1, brain-derived neurotrophic factor (BDNF), neurotrophin-4, and C-reactive protein (CRP). This assay has low intra- (\<10%) and inter-assay (7--23%) variation and has lower limits of detection lower than reported median plasma concentrations of these cytokines/inflammatory factors in normal neonates.

The 'NEC group' was comprised of all preterm neonates enrolled in the NICHD cytokine study with a diagnosis of NEC (Bell's stages II and III) ([@R16]). All other infants were included in the control group. Demographic and clinical data, including gestational age, birth weight, gender, ethnicity, history of sepsis, postnatal age when feeds were started, age when full enteral feeds were achieved, and age at onset of NEC were obtained from the NRN generic database. Frequencies (percentage), means, standard deviations, median values, and ranges were computed for demographic data and cytokine concentrations. Frequencies were compared by the Fisher's exact test. We compared (a) peak cytokine concentrations in NEC *vs*. control groups; (b) cytokine concentrations in NEC group prior to onset of NEC *vs*. controls; and (c) samples drawn from the NEC group 'before NEC' *vs*. 'after NEC' group, using the Student's *t* test or when the variance in the two groups was unequal, the Welch-Satterthwaite *t-*test.

To identify clinical characteristics and cytokines associated with NEC, we performed a stepwise logistic regression analysis. Univariate logistic regression models were first used to evaluate the association between NEC and categorical predictors such as gender (1 = male, 2 = female), ethnicity (1 = African-American, 2 = Caucasian, 3 = other), and sepsis (1 = yes, 0 = no), and then with continuous predictors (gestational age, birth weight and cytokines). Variables identified in the univariate analysis at *p*\<0.20 (and some other covariates that were not significant but were biologically-plausible, such as gender) were then used to develop a multivariate survival model. Cytokines were considered time-dependent and right-censored (because many infants developed NEC after the end of the study period) covariates. For categorical predictors, we examined Kaplan-Meier curves and then used the log-rank test for equality across strata to identify predictors (*p*\<0.25) to be included in the final model. For continuous variables, a univariate Cox proportional hazard regression model was used to identify predictors to be included in the multivariate analysis.

To determine the diagnostic usefulness of blood TGF-β levels, we computed receiver operating characteristics (ROCs) and selected a TGF-β concentration with the highest sum of sensitivity and specificity for further evaluation as a diagnostic 'cut-off' value. The accuracy of this cut-off value in correctly classifying infants into the NEC and control groups was computed using a 2 × 2 confusion matrix of the predicted and observed number of cases. To determine whether the diagnostic accuracy of TGF-β could be improved by adding other cytokines or clinical characteristics to the ROC model, we performed logistic regression and identified covariates associated with NEC at *p*\<0.20. These covariates were then evaluated using inclusive (with all variables) and reduced models.

RESULTS {#S7}
=======

Patient characteristics {#S8}
-----------------------

A total of 1067 infants with birth weights between 410--1000 grams were admitted to the participating centers during the study period and were enrolled in the study within 72 hours. In the final analysis, 997 infants were included; 70 neonates were excluded due to death in the first 7 days (n = 43), birth defects (n = 13), or early-onset sepsis (n = 14).

NEC was recorded in 104/997 (10.4%) infants at a median age of 23.5 days (range 1--114 days). The distribution of gestational age, birth weight, and gender was similar in NEC and control groups ([Table 1](#T1){ref-type="table"}). The NEC group had a higher percentage of African-American infants (61/104, 58.6% in the NEC group *vs*. 423/997, 47.4% controls, *p* = 0.02) and also had a higher incidence of sepsis (52.9 vs. 41.6%, *p* = 0.02).

Longitudinal changes in blood cytokines {#S9}
---------------------------------------

All cytokines showed significant time trends (*p\<*0.05) during the first 3 postnatal weeks. IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, LT-α, GM-CSF, and NT-4 showed a decreasing trend over time, whereas IL-18, BDNF, MIP-1β/CCL4, MMP-9, RANTES/CCL5, TGF-β1, and CRP increased with postnatal age. Infants in the NEC group had lower TGF-β levels over the study period than controls (median 1871, range 467--11431 pg/mL *vs*. 2501, range 202--12750 pg/mL, *p*\<0.05). There was also a trend towards lower IL-2 concentrations in the NEC group (median 58, range 3--430 pg/mL *vs*. 70, range 3--3118 pg/mL, *p*=0.07). In contrast, IL-8/CXCL8 levels were higher in the NEC group than controls (median 4527, range 297--837973 pg/mL *vs*. 4069, range 130--674431 pg/mL, *p*\<0.05). These data are summarized in [Table 2](#T2){ref-type="table"}.

Clinical characteristics and cytokines associated with NEC {#S10}
----------------------------------------------------------

In univariate logistic regression, the following variables were associated with NEC: gender, ethnicity, sepsis, birth weight, IL-2, IL-17, LT-α, MIP-1α/CCL3, RANTES/CCL5, IL-8/CXCL8, TGF-β1, and BDNF. Each of these variables was included in a time-dependent multivariate survival model. After controlling for other covariates, gender, ethnicity, sepsis, IL-2, IL-8/CXCL8, and TGF-β1 remained significant. A reduced model containing these 6 variables was fitted to the data ([Table 3](#T3){ref-type="table"}). In the case of ethnicity, African-American was the reference cell, and infants of non-Caucasian, non-African-American ethnicity were at the highest risk (hazard ratio = 2.6× African-American infants) of NEC. Sepsis increased the risk of NEC by 46%. Female gender and Caucasian race were protective, associated with a 23% and 35% lower risk, respectively. For every unit increase in TGF-β1 and IL-2 concentration, the risk of NEC decreased by 0.1%.

Blood cytokines prior to onset of NEC {#S11}
-------------------------------------

To determine whether infants in the NEC group showed a unique cytokine signature even before they developed NEC, we compared samples from the NEC group drawn prior to onset of NEC *vs*. controls ([Figure 1](#F1){ref-type="fig"}). The NEC group showed lower TGF-β levels than controls at all time-points (D1: median 1090, range 50--7305 pg/mL *vs*. 1301, 56--7380 pg/mL in controls; D3: 988, 50--6869 *vs*. 1286, 0--7095 pg/mL in controls; D7: 1073, 50--5364 *vs*. 1487, 9--6978 pg/mL in controls; D14: 1573, 50--5677 *vs*. 1952, 50--10022 pg/mL in controls; D21: 1701, 98--11431 *vs*. 2129, 50--12750 pg/mL in controls; *p*\<0.05 for all sub-groups). The NEC group also had lower IL-18, MIP-1α/CCL3, RANTES/CCL5, and MMP-9 on D3, lower MIP-1α/CCL3, and RANTES/CCL5 on D7, and lower IL-17 levels on D21 ([Table 4](#T4){ref-type="table"}).

Association of TGF-β with NEC {#S12}
-----------------------------

To determine whether blood TGF-β levels could discriminate between the NEC *vs*. control groups, we computed ROCs of TGF-β using data from all the cases before they developed NEC and controls ([Figure 2](#F2){ref-type="fig"}). The area under the curve (AUC) was 0.67, indicating "fair" diagnostic accuracy. Inclusion of other clinical variables or cytokines did not improve the accuracy of this model. A 'cut-off' TGF-β = 1380 pg/mL (at the best sensitivity and specificity coordinates) classified infants into the NEC or control group with 64.0% accuracy (95% confidence interval 60.9% -- 66.9%; [Table 5](#T5){ref-type="table"}). The sensitivity and specificity were 68% and 46% on D1 and D3, 64% and 56% on D7, and 40% and 74.4%, respectively, on D14 and D21. The AUC improved to 0.71 when ROCs were computed using cumulative TGF-β values.

To confirm that low TGF-β levels in infants who went on to develop NEC were not an artifact arising from exclusion of samples from later time-points, we compared TGF-β levels in the NEC *vs*. control groups as a function of post-menstrual age (PMA). NEC group had lower TGF-β levels at PMAs of 25 weeks (median 897, range 50--7305 pg/mL vs. 1382, range 50--7023 pg/mL in controls; *p*=0.02) and 27 weeks (median 1073, range 50--5677 pg/mL vs. 1646, range 9--9484 pg/mL; *p*\<0.0001), and showed a trend towards lower levels at PMA 26 and 28--29 weeks. The number of samples at other PMAs was not adequate for analysis.

TGF-β levels showed a small but significant negative correlation with the postnatal age at first enteral feed (Pearson's *r* = −0.09 in complete data set, *p* = 0.007) and when full enteral feeds were achieved (*r* = −0.11, *p* = 0.001). TGF-β levels also correlated negatively with death before discharge (*r* = −0.14, *p \<*0.0001).

Changes in cytokine concentrations after the onset of NEC {#S13}
---------------------------------------------------------

To identify cytokine biomarkers of NEC, we compared samples drawn from the NEC group before *vs*. after the onset of NEC. Summary statistics for cytokines that showed significant differences on D7, D14, and D21 are depicted in [Table 6](#T6){ref-type="table"}. There was a trend towards lower TGF-β levels in samples drawn after NEC but the difference did not reach statistical significance.

DISCUSSION {#S14}
==========

We identified male gender, non-Caucasian/non-African-American ethnicity, history of sepsis, lower blood TGF-β~1~ and IL-2 levels, and higher IL-8/CXCL8 levels to be associated with NEC in ELBW infants. Although infants who went on to develop NEC showed important differences in blood cytokine levels compared to controls starting on the day of birth, it was the clinical parameters, and not cytokines, that accounted for most of the risk of NEC in our statistical models. These findings are consistent with earlier observations in bronchopulmonary dysplasia ([@R17]), indicating that clinical variables may be driving the association of these cytokines with NEC, rather than *vice versa*. Our observations of increased risk of NEC in male infants and in certain ethnic groups are consistent with previous reports ([@R18],[@R19]). The risk of NEC in non-Caucasian/non-African-American infants is consistent with the recent data showing higher NEC-related morbidity in Latinos ([@R19]), but not with earlier studies that identified African-American neonates to be at the highest risk ([@R18],[@R19]). Although some of these disparities could be due to differences in access to prenatal care, specific genetic factors may also be at play.

In our study, ELBW infants who went on to develop NEC started with low circulating TGF-β~1~ since D1. Blood TGF-β~1~ concentrations \<1380 pg/mL predicted NEC with 64% accuracy. Although several biomarkers (such as the inter-alpha inhibitor protein, intestinal fatty acid-binding protein, hexosaminidase, proapolipoprotein CII, and *des*-arginine serum amyloid A) have been identified for their ability to discriminate between confirmed NEC and other causes of feeding intolerance ([@R20]--[@R23]), blood TGF-β~1~ is the first biomarker to estimate the risk of NEC in a newly-born premature infant. Despite moderate diagnostic accuracy, the ability of blood TGF-β~1~ to identify at-risk infants several weeks before the actual development of NEC has the potential to change clinical practice, allowing targeted application of splanchnic perfusion/oxygenation monitors, devices that are potentially-useful but are expensive or cumbersome for universal use in neonatal intensive care units, or the use of banked human milk and probiotics, interventions that are promising but of unproven safety in ELBW infants ([@R24],[@R25]). Although a predictive accuracy of 64% may appear modest, it may be a major advance in our ability to estimate the risk of NEC in a premature infant on the 1st postnatal day -- a rise from our current accuracy levels of 5--15% based on data on incidence of NEC by gestational age. The NPV of 93% is similarly modest (in a cohort with 10% incidence of NEC, a randomly-chosen sample should show an NPV of 90%) but may be clinically important; most premature infants with abdominal signs are currently treated presumptively for NEC even when they do not have NEC, and in this context, even a small improvement in risk-stratification may be useful.

Our findings of low blood TGF-β levels in the NEC group are consistent with our previous reports where we showed that preterm neonates may be at risk of inflammatory mucosal injury and NEC because of a developmental deficiency of TGF-β isoforms TGF-β~1~ and TGF-β~2~ in the intestine ([@R12],[@R26]). We demonstrated that TGF-β normally suppresses the inflammatory responses of resident intestinal macrophages, thereby promoting mucosal tolerance to bacterial products ([@R12]). However, in the TGF-β-deficient preterm intestine, macrophages produce an exaggerated cytokine response upon exposure to bacterial products ([@R12]). In addition to its effects on macrophages, TGF-β also restricts the Th1 and Th2 gut lymphocyte pools by suppressing T-cell trafficking, increasing apoptosis in activated T-cells, and promoting the development of regulatory T cells ([@R27]). The anti-inflammatory effects of TGF-β are evident in TGF-β~1~-deficient mice, which develop mucosal and systemic inflammation within a few weeks after birth ([@R28]).

Circulating TGF-β originates from diverse cellular sources including platelets, monocytes/macrophages, lymphocytes, epithelium, and mesenchymal cells ([@R27]), and is comprised mostly of latent TGF-β bound to α2-macroglobulin along with a small pool of free, active TGF-β that is rapidly taken up and degraded in peripheral tissues. In infants who developed NEC, there are 3 possible explanations for the low circulating TGF-β levels. The first is increased peripheral uptake of TGF-β to compensate for low tissue expression. Peripheral consumption of TGF-β has been described in patients with Guillain-Barré syndrome, who have low plasma TGF-β levels despite evidence of increased production ([@R29]). Consistent with this hypothesis, we have previously shown that TGF-β expression is decreased in healthy margins of tissues resected for NEC ([@R12]). A second explanation for low circulating TGF-β levels is based on an assumption that the developing intestine is a major contributor to circulating TGF-β levels. Because TGF-β expression increases in the intestine as a function of gestational maturation, lower tissue expression of TGF-β in infants who developed NEC could conceivably reflect an underlying state of arrested mucosal development, where low TGF-β expression may indicate persistence of a cytokine profile corresponding to an earlier, less mature developmental epoch ([@R30],[@R31]). In support of this possibility, we detected lower TGF-β levels in NEC group than in controls at the same post-menstrual age. Finally, infants who developed NEC may constitutively produce less TGF-β than controls due to genetic/epigenetic factors. Polymorphisms in the TGF-β1 gene such as G915C, C-509T, and T869C are common in the general population and are associated with higher blood TGF-β levels ([@R32]), although the significance of these genetic markers is unclear in NEC. We have recently shown that NEC is associated with dimethylation of the lysine 9 residue of histone 3 in the TGF-β nucleosome, a repressive modification associated with facultative heterochromatin assembly and transcriptional silencing ([@R26]). Further study is needed to determine the timing of these epigenetic changes in at-risk infants.

We did not find support for our second hypothesis as we did not detect elevated cytokine levels at early time-points in the NEC group. Prior to the development of NEC, infants in the NEC group had significantly low IL-18, MIP-1β/CCL4, and RANTES/CCL5, and a tendency for most other cytokines to be lower than controls. Interestingly, NEC is marked by a paucity of T-cells, which are a major cellular source of many of these cytokines ([@R33]--[@R35]). We also detected low IL-2 levels in our NEC patients on D14 and D21. IL-2 is a Th1-derived cytokine that promotes proliferation and activation of CD4+ and CD8+ lymphocytes, and an IL-2-deficient state may result in limited T-cell lifespan and proliferation. However, low levels of IL-6 and CRP, which are mainly produced in the liver, indicate that these defects may extend beyond the intestine ([@R36]).

The diagnosis of NEC was associated with increased expression of IL-6, IL-8/CXCL8, IL-10, IL-18, MCP-1/CCL2, MIP-1β/CCL3, CRP, and NT-4. Elevated IL-8/CXCL8, IL-6, and IL-18 levels have noted previously during NEC ([@R3]--[@R6],[@R37]) and are adversely associated with disease severity and with short-term survival in NEC ([@R4],[@R38]). IL-6 has a shorter half-life and may be detectable only for short periods after onset of NEC ([@R39]), whereas IL-8/CXCL8 levels may show sustained elevation and correlate with the severity of illness over a period of time ([@R5]). Increased IL-6 and CRP in NEC support the presence of a gut-liver inflammatory axis, where the transfer of bacterial products and inflammatory mediators into the portal circulation amplifies the production of cytokines and nitric oxide in the liver. These mediators then exacerbate intestinal injury via enterohepatic circulation, setting up a feed-forward loop of inflammation ([@R40]). The major strengths of our study are a large sample of ELBW infants recruited from multiple sites, prospective data collection by trained observers, and measurement of multiple cytokines at serial time-points, including well before the onset of NEC. An important limitation is its exclusive reliance on circulating levels of cytokines, which does not identify the cellular sources or the effector cells that are likely to respond to these cytokines. We were also limited by exclusion of infants with early-onset sepsis (n=16), who would have comprised an important comparison group. We were unable to evaluate the effects of human milk *vs*. formula feeding, gut microbiota, and chorioamnionitis, each of which may alter or reprogram infant cytokine profiles, due to limitations of the retrospective study design. Finally, the NICHD Cytokine Study was designed to investigate cytokine predictors of neurodevelopmental impairment, and therefore, the cytokine panel was comprised of analytes generally associated with systemic inflammation and not specifically with gut mucosal injury. This panel included TGF-β~1~ but not TGF-β~2~, and further study is needed to determine the relationship of blood TGF-β~2~ levels with NEC. It may also be possible to improve the predictive accuracy of blood TGF-β levels by combining these data with other clinical predictors of NEC ([@R2]) such as absence/reversal of umbilical blood flow on prenatal Doppler examination or histopathological evidence of chorioamnionitis.

CONCLUSIONS {#S15}
===========

Male gender, non-Caucasian/non-African-American ethnicity, sepsis, lower blood TGF-β and interleukin (IL)-2 levels, and higher IL-8 levels were associated with NEC. Blood TGF-β concentrations \<1380 pg/mL predicted NEC with about 64% accuracy on the day of birth. We did not find support for our second hypothesis that infants who develop NEC have higher cytokine levels in early neonatal period.
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![Receiver-operator characteristics (ROC) of TGF-β in blood spots from infants in the NEC (drawn before the onset of NEC) and control groups. Red markers on the curve indicate TGF-β concentrations. A cut-off TGF-β level of 1380 pg/mL (marked by broken lines in the figure) correctly classified 61.2% infants in the NEC group (true positives) but gave a false-positive result in 35.7% controls.](nihms554620f2){#F2}

###### 

Demographic and clinical information

  Variable Name                         NEC group                              Controls[1](#TFN1){ref-type="table-fn"}
  ------------------------------------- -------------------------------------- -----------------------------------------
  Total cases                           104                                    893
  Birth weight (mean ± SD)              750.2 ± 137.4                          766.9 ± 140.3
  Gestational age (weeks) (mean ± SD)   25.93 ± 1.9                            25.64 ± 1.6
  Gender (% male)                       52.9                                   47.4
  Ethnicity                                                                    
   African American (%)                 58.6[\*](#TFN2){ref-type="table-fn"}   47.4[\*](#TFN2){ref-type="table-fn"}
   White (%)                            24.0                                   31.7
   Others (%)                           17.3                                   20.9
  Tocolytics                            48.5                                   41.2
  Antenatal steroids (%)                83.6                                   76.4
  Postnatal steroids (%)                28.8                                   25.9
  Ventilator days (mean ± SD)           28.5 ± 25.3                            24.3 ± 25.0
  Days on oxygen (mean ± SD)            57.4 ± 39.8                            57.7 ± 38.2
  Sepsis (%)                            52.9[\*](#TFN2){ref-type="table-fn"}   41.6[\*](#TFN2){ref-type="table-fn"}

Total number of controls with complete information varies by variable.

Statistical significant differences at 5% level.

###### 

Summary statistics for peak cytokine concentrations in cases and controls

  Cytokine         Cases                                      
  ---------------- --------- --------- ---------- ----------- ------------
  IL-1β            104       15        173        366         2560
  IL-2             104       3         58         73          430
  IL-4             104       17        152        186         934
  IL-5             104       11        154        199         1405
  IL-6             104       11        180        644         2916
  IL-12            104       3         143        214         2560
  IL-17            104       32        204        337         1910
  IL-18            104       379       2236       2606        8778
  TNF              104       14        76         115         598
  LT-α             104       8         349        489         2939
  IFN-γ            104       3         241        283         1106
  GM-CSF           104       6         145        185         1943
  MCP-1/CCL2       104       27        3972       4421        18876
  MIP-1α/CCL3      104       53        257        1209        38308
  MIP-1β/CCL4      104       455       1435       1904        11196
  RANTES/CCL5      104       5920      134980     168124      672487
  **IL-8/CXCL8**   **104**   **297**   **4527**   **27797**   **837973**
  IL-10            104       186       601        905         9854
  **TGF-β~1~**     **104**   **467**   **1871**   **2258**    **11431**
  MMP-9            104       330822    2279251    5316557     156598823
  sIL-6R           104       557008    2381457    7130013     99240278
  TREM-1           104       459       3396       4048        15318
  BDNF             104       1249      6574       10296       80448
  CRP              104       79283     1339088    1962031     9465221
  NT4              104       10        95         114         348

  Control   p-value                                       
  --------- --------- ---------- ----------- ------------ ----------
  893       3         200        368         4174         0.96
  893       3         70         97          3118         0.07
  893       3         163        212         2560         0.26
  893       14        141        191         3354         0.73
  893       3         185        540         45838        0.59
  893       3         158        220         2560         0.86
  893       17        219        355         2330         0.64
  893       394       2330       2673        9830         0.67
  893       3         89         138         7647         0.40
  893       6         397        564         4076         0.15
  893       3         236        337         18285        0.41
  893       6         149        173         1710         0.42
  893       6         3938       5429        666884       0.65
  893       35        269        1105        52060        0.82
  893       173       1445       2003        20480        0.62
  893       4092      151540     188248      1889398      0.20
  **893**   **130**   **4069**   **12216**   **674431**   **0.00**
  893       3         558        733         68186        0.46
  **893**   **202**   **2501**   **2891**    **12750**    **0.00**
  893       136170    2441515    5391204     228077636    0.97
  893       25400     2497814    10097313    1157003158   0.60
  893       313       3463       4277        116609       0.65
  893       256       8493       12872       239635       0.17
  893       2000      1408200    2146945     14795169     0.36
  893       3         114        127         841          0.13

Peak calculated as the Maximum Cytokine for each infant.

For Cases: Peak calculated using all sample days

For Controls: Peak calculated using all sample days

Testing the average values, test is a two sample t-test

###### 

Estimated multiplicative effect (SE) and test-statistics for H0: beta=0 for Multivariate Model

  Variable                Coefficient   Exponentiated coefficient (SE)   Wald Test (*p*-value)
  ----------------------- ------------- -------------------------------- -----------------------
  Gender                  −0.25452      0.77529 (0.09689)                −2.627 (*0.009*)
  Ethnicity (Caucasian)   −0.43201      0.64921 (0.10164)                −4.250 (*\<0.001*)
  Ethnicity (Other)       0.95866       2.60820 (0.24519)                3.909 (*\<0.001*)
  Sepsis                  0.38161       1.46464 (0.09697)                3.935 (*\<0.001*)
  IL-2                    −0.00444      0.99557 (0.00116)                −3.815 (*\<0.001*)
  IL-8/CXCL8              0.000003      1.00000 (0.000001)               3.065 (*0.002*)
  TGF-β~1~                −0.00019      0.99981 (0.00005)                −4.141 (*\<0.001*)

Log-likelihood=−2806.555

###### 

Summary statistics for cytokine concentrations in cases prior to NEC *vs*. controls summarized by day of measurement

  Cytokine      Cases before onset of NEC   Controls   p-value                                                                      
  ------------- --------------------------- ---------- --------- --------- ---------- ----- ------- --------- --------- ----------- --------
                ***Postnatal Day 1***                                                                                               
                                                                                                                                    
  BDNF          61                          342        2741      3658      26312      470   206     3438      4453      103033      *0.04*
  TGF-β         61                          50         1090      1272      7305       470   56      1301      1586      7380        *0.02*
                                                                                                                                    
                ***Postnatal Day 3***                                                                                               
                                                                                                                                    
  IL-18         90                          247        1066      1503      6016       837   6       1255      1549      7077        *0.02*
  MIP-1α/CCL3   90                          6          124       705       19945      837   6       154       677       50534       *0.02*
  MMP-9         90                          21149      751355    1827173   37067238   837   21096   1087801   2294486   185309104   *0.01*
  RANTES/CCL5   90                          2159       63127     74585     417270     837   1590    75081     94666     678668      *0.03*
  TGF-β         90                          50         988       1205      6869       836   0       1286      1540      7095        *0.03*
                                                                                                                                    
                ***Postnatal Day 7***                                                                                               
                                                                                                                                    
  MIP-1α/CCL3   86                          6          120       762       16739      747   6       141       659       35707       *0.02*
  RANTES/CCL5   86                          4411       69165     80531     417052     747   666     84589     109406    1303609     *0.01*
  TGF-β         86                          50         1073      1376      5364       748   9       1487      1697      6978        *0.01*
                                                                                                                                    
                ***Postnatal Day 14***                                                                                              
                                                                                                                                    
  IL-2          68                          3          25        36        155        808   3       37        54        616         *0.01*
  IL-4          68                          3          78        104       693        805   1       97        134       2560        *0.04*
  TGF-β         68                          50         1573      1855      5677       808   50      1952      2259      10022       *0.04*
                                                                                                                                    
                ***Postnatal Day 21***                                                                                              
                                                                                                                                    
  IL-2          52                          3          24        35        171        748   2       38        54        560         *0.04*
  IL-17         52                          3          107       163       737        748   1       153       229       2330        *0.04*
  BDNF          52                          425        5309      9808      80448      749   24      7176      10468     239635      *0.05*
  NT-4          52                          3          37        41        196        748   0       43        53        403         *0.04*
  TGF-β         52                          98         1701      2064      11431      749   50      2129      2463      12750       *0.05*

###### 

Diagnostic value of TGF-β~1~ \<1380 pg/mL as a predictive marker for NEC

                                                                                95% Confidence Interval   
  ---------------------------------------------------------------------- ------ ------------------------- ------
  Prevalence                                                             0.1    0.09                      0.12
  Sensitivity                                                            0.61   0.51                      0.7
  Specificity                                                            0.64   0.61                      0.67
  For any particular test result, the probability that it will be:                                        
  Positive                                                               0.38   0.35                      0.41
  Negative                                                               0.62   0.59                      0.65
  For any particular positive test result, the probability that it is:                                    
  True Positive                                                          0.16   0.13                      0.21
  False Positive                                                         0.84   0.79                      0.87
  For any particular negative test result, the probability that it is:                                    
  True Negative                                                          0.93   0.91                      0.95
  False Negative                                                         0.07   0.05                      0.09
  Likelihood Ratios:                                                                                      
  Positive                                                               1.71   1.43                      2.04
  Negative                                                               0.6    0.47                      0.77

###### 

Cytokine concentrations in the NEC group before and after onset of NEC

                Samples drawn from infants who were yet to develop NEC   Samples drawn from infants who had already developed NEC   p-value                                                                  
  ------------- -------------------------------------------------------- ---------------------------------------------------------- --------- --------- --------- ---- ------- --------- --------- --------- --------
                ***Postnatal Day 7***                                                                                                                                                                        
                                                                                                                                                                                                             
  CRP           86                                                       2000                                                       427664    719224    4711390   5    73130   2449122   2518116   5000000   *0.04*
                                                                                                                                                                                                             
                ***Postnatal Day 14***                                                                                                                                                                       
                                                                                                                                                                                                             
  IL-1β         68                                                       3                                                          89        176       860       23   3       132       334       2560      *0.05*
  IL-6          68                                                       3                                                          68        163       2560      23   3       142       705       2916      *0.00*
  MCP-1/CCL2    68                                                       21                                                         1761      2698      15639     23   242     3668      4478      18876     *0.02*
  MIP-1β/CCL4   68                                                       6                                                          978       1242      5749      23   460     1165      2137      11196     *0.02*
  IL-8/CXCL8    68                                                       206                                                        1872      5183      102627    23   786     8233      26107     280505    *0.01*
  IL-10         68                                                       3                                                          316       353       997       23   33      397       844       5022      *0.00*
                                                                                                                                                                                                             
                ***Postnatal Day 21***                                                                                                                                                                       
                                                                                                                                                                                                             
  IL-6          52                                                       3                                                          54        99        788       30   3       110       458       2560      *0.00*
  IL-17         52                                                       3                                                          107       163       737       30   3       197       273       929       *0.02*
  CRP           52                                                       14600                                                      836001    1070676   3963497   30   2000    1414326   1715967   7177201   *0.03*
